Wilbanks Smith & Thomas Asset Management LLC Argenx Se Transaction History

Wilbanks Smith & Thomas Asset Management LLC

$3.54 Billion
Q1 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2018 Feb 08, 2019	SELL	$63.81 - $109.82 $44,667 - $76,874	-700 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$75.5 - $96.63 $52,850 - $67,641	700 New	700 $53,000

Others Institutions Holding ARGX

# of Institutions

358

Shares Held

31.3M

Call Options Held

212K

Put Options Held

210K

Price T Rowe Associates Inc Baltimore, MD

5.5M
Shares

$2.72 Billion
0.27% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

3.19M
Shares

$1.58 Billion
1.93% of portfolio
Janus Henderson Group PLC London, X0

2.22M
Shares

$1.1 Billion
0.49% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

2.12M
Shares

$1.05 Billion
0.51% of portfolio
Capital World Investors Los Angeles, CA

1.86M
Shares

$922 Million
0.13% of portfolio

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $27.4B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wilbanks Smith & Thomas Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wilbanks Smith & Thomas Asset Management LLC with notifications on news.

Account